NASDAQ: AMGN · Life Sciences · 3 alerts · CIK 318154
Share price
$462.32Close, Nov 16
Market cap
$250B
Shares outstanding
540.91MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Amgen Inc filings on SEC EDGAR ↗
Amgen reported total revenues of $10.37 billion for the third quarter of 2026, an 8% increase compared to the same period in 2025, driven primarily by product sales growth. Net income rose to $3.86 billion, or $7.08 per diluted share, benefiting from higher operating income and significant other income gains.
Amgen reported third quarter 2026 financial results with total revenues increasing 8% year-over-year to $10.4 billion, driven by volume growth across its commercial portfolio. GAAP EPS rose 19% to $7.08, while the company generated $3.7 billion in free cash flow during the period.
Term
Q3 2026
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”
Robert A. Bradway, chairman and chief executive officer
Amgen Inc. has appointed David W. Gibbs, the former CEO of Yum! Brands, to its Board of Directors, effective immediately. Mr. Gibbs will serve on the Audit and Compensation committees, bringing the total board size to 13 directors. He will receive the company's standard non-employee director compensation, including a pro-rated annual cash retainer and restricted stock units.